「核心医疗」获超1亿美元D轮融资，累计完成700余例人工心脏植入手术｜36氪首发

Core Insights - Core Medical has completed over $100 million in Series D financing, marking the largest investment in China's innovative medical device sector since 2025 [1] - The funding will be used for product development and to advance the company's international strategy [1] - Core Medical focuses on high-end innovative medical devices, particularly artificial hearts and mechanical circulatory support devices [1][4] Market Opportunity - There is a significant shortage of heart donors in China, with fewer than 1,000 heart transplants performed annually and less than 80 qualified medical institutions [1] - With approximately 16 million chronic heart failure patients in China, the potential market for heart failure devices is estimated to be in the hundreds of billions [1] Product Development - Core Medical's flagship product, the Corheart 6, features an axial full magnetic suspension design, weighing only 90g for the pump and 800g for the external device, with a battery life of 33 hours [4] - The company has completed over 700 implant surgeries with Corheart 6 and is developing a dual-chamber support system, DuoCor, which has already seen clinical applications [5] - Core Medical is also advancing its interventional artificial heart product, CorVad, which has achieved breakthroughs in micro-motor technology [5] International Expansion - Clinical trials for Corheart 6 are underway in Austria and Germany, with DuoCor having completed its first humanitarian implant in Hannover, Germany [5][6] - The stable market environment and strong healthcare payment systems in Europe are seen as strategic advantages for the company's global expansion [6] Investor Perspectives - Investors, including Zhengxin Valley Capital and Junlian Capital, express confidence in Core Medical's leadership in the ventricular assist device (VAD) sector and its innovative capabilities [7][8] - The company is recognized for its comprehensive product offerings that address the clinical needs of heart failure patients [8][9] - Core Medical's first LVAD product achieved the highest market share in its first year, with a second pVAD product currently in the registration phase [9]